Kadmon Holdings, Inc.: Lead candidate is KD025, a ROCK2 inhibitor in in a pivotal clinical trial for chronic graft-versus-host disease (cGVHD); study outcome to be reported by YE 2019. Ph2 trial of KD025 in systemic sclerosis ongoing. Also developing KD033, anti-PD-L1/IL-15 fusion protein; exp to enter the clinic Q4 2019. FDA approval received Sept 2019 for Wilson's disease indication (generic trientine capsules).
Based in...
Clinical Stage
Phase l or ll
Disease Space
Autoimmune, Fibrosis, Oncology
Biotechnology, Pharmaceuticals
Public, USA
Market Cap
100MM - 500MM
450 East 29th Street
New York, NY 10016
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Upcoming Company Event Participation

Solebury Trout Management Access: SF 2020

San Francisco, CA, United States, January 13 – January 16, 2020

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2019 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.